Learn how to improve Bioanalytical clinical outcomes by performing MetID characterisation. Leading experts Heather Heading and Andrew Taylor discuss how the quick identification of metabolites in both Invivio and Invitro samples can help accelerate programs through first-in-human trials.
About this webinar
Profiling, characterising, and identifying metabolites are key steps in supporting drug discovery and development of novel compounds. Metabolite identification (MetID) studies help you to understand the presence of potential active or reactive metabolites and observe the unique metabolites in your compound to better understand your molecule’s biotransformation capabilities. SEKISUI XenoTech and Agilex Biolabs’ combination of in-depth scientific knowledge in drug metabolism and mass spectrometry, extensive pharmaceutical industry experiences, and advanced software, can quickly identify metabolites in both in vivo and in vitro samples and help accelerate sponsors’ drug development programs through FIH clinical trials.
Key discussions in this webinar will include:
- The use of MetID for tox species selection.
- How to improve bioanalytical clinical outcomes by performing MetID characterisation.
- How metabolite characterisation helps troubleshoot problems earlier in the drug program.
- Test system selection for in vitro MetID.
- Integrating MetID with your bioanalytical program and how the two corelate.
- Why metabolite characterization studies are not quantitative.
- Regulatory expectations for MetID
About the Presenters:
Heather Heading is currently the Director of LCMS at Agilex Biolabs. She obtained her Bachelor of Science with Honours and a Bachelor of Technology from the world-renowned Flinders University in South Australia where she then joined Agilex Biolabs in 2009. Now Heather is responsible for the management and oversight of the Agilex Biolabs LC-MSMS division and works closely across the various departments to ensure her clients are provided with an exceptional customer experience. She is passionate about bringing new medicine to market for a healthier world and sees the crucial role that her work with Agilex Biolabs does as a vital part of this process.
Andrew G. Taylor, PhD, received his PhD from University of California San Diego. He joined SEKISUI XenoTech as a research scientist in 2017, serving as a Study Director in nonclinical drug interaction contract studies in compliance with Good Laboratory Practices (GLP), OECD Principles of GLP, &/or Japan MOHW GLP Standards and specializing in drug transport and drug metabolism studies. He became the Technical Support Manager for services in 2020 and provides valuable guidance to ensure research needs are being met.
